#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0004] 2.
1-1	0-1	[	_	_	
1-2	1-5	0004	_	_	
1-3	5-6	]	_	_	
1-4	7-8	2	_	_	
1-5	8-9	.	_	_	

#Text=Description of the Related Art
#Text=[0005] A method of acquiring information about a subject has been used to measure the concentration of a component contained in a body fluid such as blood, other body fluids in the subject or excised tissue, thereby to achieve accurate diagnosis, fast determination of treatment course, and improved healthcare.
2-1	10-21	Description	_	_	
2-2	22-24	of	_	_	
2-3	25-28	the	_	_	
2-4	29-36	Related	_	_	
2-5	37-40	Art	_	_	
2-6	41-42	[	_	_	
2-7	42-46	0005	_	_	
2-8	46-47	]	_	_	
2-9	48-49	A	_	_	
2-10	50-56	method	_	_	
2-11	57-59	of	_	_	
2-12	60-69	acquiring	_	_	
2-13	70-81	information	_	_	
2-14	82-87	about	_	_	
2-15	88-89	a	_	_	
2-16	90-97	subject	_	_	
2-17	98-101	has	_	_	
2-18	102-106	been	_	_	
2-19	107-111	used	_	_	
2-20	112-114	to	_	_	
2-21	115-122	measure	_	_	
2-22	123-126	the	_	_	
2-23	127-140	concentration	_	_	
2-24	141-143	of	_	_	
2-25	144-145	a	_	_	
2-26	146-155	component	_	_	
2-27	156-165	contained	_	_	
2-28	166-168	in	_	_	
2-29	169-170	a	_	_	
2-30	171-175	body	_	_	
2-31	176-181	fluid	_	_	
2-32	182-186	such	_	_	
2-33	187-189	as	_	_	
2-34	190-195	blood	_	_	
2-35	195-196	,	_	_	
2-36	197-202	other	_	_	
2-37	203-207	body	_	_	
2-38	208-214	fluids	_	_	
2-39	215-217	in	_	_	
2-40	218-221	the	_	_	
2-41	222-229	subject	_	_	
2-42	230-232	or	_	_	
2-43	233-240	excised	_	_	
2-44	241-247	tissue	_	_	
2-45	247-248	,	_	_	
2-46	249-256	thereby	_	_	
2-47	257-259	to	_	_	
2-48	260-267	achieve	_	_	
2-49	268-276	accurate	_	_	
2-50	277-286	diagnosis	_	_	
2-51	286-287	,	_	_	
2-52	288-292	fast	_	_	
2-53	293-306	determination	_	_	
2-54	307-309	of	_	_	
2-55	310-319	treatment	_	_	
2-56	320-326	course	_	_	
2-57	326-327	,	_	_	
2-58	328-331	and	_	_	
2-59	332-340	improved	_	_	
2-60	341-351	healthcare	_	_	
2-61	351-352	.	_	_	

#Text=To measure the concentration of each component of a body fluid, the body fluid must be extracted from the subject by blood collection.
3-1	353-355	To	_	_	
3-2	356-363	measure	_	_	
3-3	364-367	the	_	_	
3-4	368-381	concentration	_	_	
3-5	382-384	of	_	_	
3-6	385-389	each	_	_	
3-7	390-399	component	_	_	
3-8	400-402	of	_	_	
3-9	403-404	a	_	_	
3-10	405-409	body	_	_	
3-11	410-415	fluid	_	_	
3-12	415-416	,	_	_	
3-13	417-420	the	_	_	
3-14	421-425	body	_	_	
3-15	426-431	fluid	_	_	
3-16	432-436	must	_	_	
3-17	437-439	be	_	_	
3-18	440-449	extracted	_	_	
3-19	450-454	from	_	_	
3-20	455-458	the	_	_	
3-21	459-466	subject	_	_	
3-22	467-469	by	_	_	
3-23	470-475	blood	_	_	
3-24	476-486	collection	_	_	
3-25	486-487	.	_	_	

#Text=The extraction of the fluid is painful.
4-1	488-491	The	_	_	
4-2	492-502	extraction	_	_	
4-3	503-505	of	_	_	
4-4	506-509	the	_	_	
4-5	510-515	fluid	_	_	
4-6	516-518	is	_	_	
4-7	519-526	painful	_	_	
4-8	526-527	.	_	_	

#Text=It damages the skin of the subject and introduces the possibility of biohazard contamination to the subject and the operator.
#Text=[0006] To solve this problem, a number of patents and journal articles describe non-invasive methods of acquiring information about analyte concentration in the tissue of human subjects.
5-1	528-530	It	*[1]	5-27[2_1]	
5-2	531-538	damages	*[1]	_	
5-3	539-542	the	*[1]	_	
5-4	543-547	skin	*[1]	_	
5-5	548-550	of	*[1]	_	
5-6	551-554	the	*[1]	_	
5-7	555-562	subject	*[1]	_	
5-8	563-566	and	*[1]	_	
5-9	567-577	introduces	*[1]	_	
5-10	578-581	the	*[1]	_	
5-11	582-593	possibility	*[1]	_	
5-12	594-596	of	*[1]	_	
5-13	597-606	biohazard	*[1]	_	
5-14	607-620	contamination	*[1]	_	
5-15	621-623	to	*[1]	_	
5-16	624-627	the	*[1]	_	
5-17	628-635	subject	*[1]	_	
5-18	636-639	and	*[1]	_	
5-19	640-643	the	*[1]	_	
5-20	644-652	operator	*[1]	_	
5-21	652-653	.	*[1]	_	
5-22	654-655	[	_	_	
5-23	655-659	0006	_	_	
5-24	659-660	]	_	_	
5-25	661-663	To	_	_	
5-26	664-669	solve	_	_	
5-27	670-674	this	*[2]	_	
5-28	675-682	problem	*[2]	_	
5-29	682-683	,	_	_	
5-30	684-685	a	_	_	
5-31	686-692	number	_	_	
5-32	693-695	of	_	_	
5-33	696-703	patents	_	_	
5-34	704-707	and	_	_	
5-35	708-715	journal	_	_	
5-36	716-724	articles	_	_	
5-37	725-733	describe	_	_	
5-38	734-746	non-invasive	_	_	
5-39	747-754	methods	_	_	
5-40	755-757	of	_	_	
5-41	758-767	acquiring	_	_	
5-42	768-779	information	_	_	
5-43	780-785	about	_	_	
5-44	786-793	analyte	_	_	
5-45	794-807	concentration	_	_	
5-46	808-810	in	_	_	
5-47	811-814	the	_	_	
5-48	815-821	tissue	_	_	
5-49	822-824	of	_	_	
5-50	825-830	human	_	_	
5-51	831-839	subjects	_	_	
5-52	839-840	.	_	_	

#Text=One of the methods is "photoacoustic spectroscopy".
6-1	841-844	One	_	_	
6-2	845-847	of	_	_	
6-3	848-851	the	_	_	
6-4	852-859	methods	_	_	
6-5	860-862	is	_	_	
6-6	863-864	"	_	_	
6-7	864-877	photoacoustic	_	_	
6-8	878-890	spectroscopy	_	_	
6-9	890-891	"	_	_	
6-10	891-892	.	_	_	

#Text=In the photoacoustic spectroscopy, the concentration of a specific substance, such as glucose or hemoglobin, contained in the blood of a subject is quantitatively determined from the acoustic waves that are generated when the subject's tissue is irradiated with short duration pulses of light of a predetermined wavelength.
7-1	893-895	In	_	_	
7-2	896-899	the	_	_	
7-3	900-913	photoacoustic	_	_	
7-4	914-926	spectroscopy	_	_	
7-5	926-927	,	_	_	
7-6	928-931	the	_	_	
7-7	932-945	concentration	_	_	
7-8	946-948	of	_	_	
7-9	949-950	a	_	_	
7-10	951-959	specific	_	_	
7-11	960-969	substance	_	_	
7-12	969-970	,	_	_	
7-13	971-975	such	_	_	
7-14	976-978	as	_	_	
7-15	979-986	glucose	_	_	
7-16	987-989	or	_	_	
7-17	990-1000	hemoglobin	_	_	
7-18	1000-1001	,	_	_	
7-19	1002-1011	contained	_	_	
7-20	1012-1014	in	_	_	
7-21	1015-1018	the	_	_	
7-22	1019-1024	blood	_	_	
7-23	1025-1027	of	_	_	
7-24	1028-1029	a	_	_	
7-25	1030-1037	subject	_	_	
7-26	1038-1040	is	_	_	
7-27	1041-1055	quantitatively	_	_	
7-28	1056-1066	determined	_	_	
7-29	1067-1071	from	_	_	
7-30	1072-1075	the	_	_	
7-31	1076-1084	acoustic	_	_	
7-32	1085-1090	waves	_	_	
7-33	1091-1095	that	_	_	
7-34	1096-1099	are	_	_	
7-35	1100-1109	generated	_	_	
7-36	1110-1114	when	_	_	
7-37	1115-1118	the	_	_	
7-38	1119-1128	subject's	_	_	
7-39	1129-1135	tissue	_	_	
7-40	1136-1138	is	_	_	
7-41	1139-1149	irradiated	_	_	
7-42	1150-1154	with	_	_	
7-43	1155-1160	short	_	_	
7-44	1161-1169	duration	_	_	
7-45	1170-1176	pulses	_	_	
7-46	1177-1179	of	_	_	
7-47	1180-1185	light	_	_	
7-48	1186-1188	of	_	_	
7-49	1189-1190	a	_	_	
7-50	1191-1204	predetermined	_	_	
7-51	1205-1215	wavelength	_	_	
7-52	1215-1216	.	_	_	

#Text=U.S.
8-1	1217-1220	U.S	_	_	
8-2	1220-1221	.	_	_	

#Text=Pat.
9-1	1222-1225	Pat	_	_	
9-2	1225-1226	.	_	_	

#Text=No. 5,348,002, WO9838904A1, WO0215776A1 describe methods for the non-invasive determination of substances in human tissue using photoacoustic measurements.
10-1	1227-1229	No	_	_	
10-2	1229-1230	.	_	_	
10-3	1231-1240	5,348,002	_	_	
10-4	1240-1241	,	_	_	
10-5	1242-1253	WO9838904A1	_	_	
10-6	1253-1254	,	_	_	
10-7	1255-1266	WO0215776A1	_	_	
10-8	1267-1275	describe	_	_	
10-9	1276-1283	methods	_	_	
10-10	1284-1287	for	_	_	
10-11	1288-1291	the	_	_	
10-12	1292-1304	non-invasive	_	_	
10-13	1305-1318	determination	_	_	
10-14	1319-1321	of	_	_	
10-15	1322-1332	substances	_	_	
10-16	1333-1335	in	_	_	
10-17	1336-1341	human	_	_	
10-18	1342-1348	tissue	_	_	
10-19	1349-1354	using	_	_	
10-20	1355-1368	photoacoustic	_	_	
10-21	1369-1381	measurements	_	_	
10-22	1381-1382	.	_	_	

#Text=The light may be visible light, infrared light, or intermediate infrared light.
#Text=[0007] In addition to hemoglobin and glucose, photoacoustic spectroscopy can be used to determine other analytes in human tissue such as cholesterol, natural fat, bilirubin, collagen, and the like.
11-1	1383-1386	The	_	_	
11-2	1387-1392	light	_	_	
11-3	1393-1396	may	_	_	
11-4	1397-1399	be	_	_	
11-5	1400-1407	visible	_	_	
11-6	1408-1413	light	_	_	
11-7	1413-1414	,	_	_	
11-8	1415-1423	infrared	_	_	
11-9	1424-1429	light	_	_	
11-10	1429-1430	,	_	_	
11-11	1431-1433	or	_	_	
11-12	1434-1446	intermediate	_	_	
11-13	1447-1455	infrared	_	_	
11-14	1456-1461	light	_	_	
11-15	1461-1462	.	_	_	
11-16	1463-1464	[	_	_	
11-17	1464-1468	0007	_	_	
11-18	1468-1469	]	_	_	
11-19	1470-1472	In	_	_	
11-20	1473-1481	addition	_	_	
11-21	1482-1484	to	_	_	
11-22	1485-1495	hemoglobin	_	_	
11-23	1496-1499	and	_	_	
11-24	1500-1507	glucose	_	_	
11-25	1507-1508	,	_	_	
11-26	1509-1522	photoacoustic	_	_	
11-27	1523-1535	spectroscopy	_	_	
11-28	1536-1539	can	_	_	
11-29	1540-1542	be	_	_	
11-30	1543-1547	used	_	_	
11-31	1548-1550	to	_	_	
11-32	1551-1560	determine	_	_	
11-33	1561-1566	other	_	_	
11-34	1567-1575	analytes	_	_	
11-35	1576-1578	in	_	_	
11-36	1579-1584	human	_	_	
11-37	1585-1591	tissue	_	_	
11-38	1592-1596	such	_	_	
11-39	1597-1599	as	_	_	
11-40	1600-1611	cholesterol	_	_	
11-41	1611-1612	,	_	_	
11-42	1613-1620	natural	_	_	
11-43	1621-1624	fat	_	_	
11-44	1624-1625	,	_	_	
11-45	1626-1635	bilirubin	_	_	
11-46	1635-1636	,	_	_	
11-47	1637-1645	collagen	_	_	
11-48	1645-1646	,	_	_	
11-49	1647-1650	and	_	_	
11-50	1651-1654	the	_	_	
11-51	1655-1659	like	_	_	
11-52	1659-1660	.	_	_	

#Text=Diagnosis of cutaneous cancer or breast cancer based on the results of the photoacoustic spectroscopy has recently proven its clinical usefulness.
12-1	1661-1670	Diagnosis	_	_	
12-2	1671-1673	of	_	_	
12-3	1674-1683	cutaneous	_	_	
12-4	1684-1690	cancer	_	_	
12-5	1691-1693	or	_	_	
12-6	1694-1700	breast	_	_	
12-7	1701-1707	cancer	_	_	
12-8	1708-1713	based	_	_	
12-9	1714-1716	on	_	_	
12-10	1717-1720	the	_	_	
12-11	1721-1728	results	_	_	
12-12	1729-1731	of	_	_	
12-13	1732-1735	the	_	_	
12-14	1736-1749	photoacoustic	_	_	
12-15	1750-1762	spectroscopy	_	_	
12-16	1763-1766	has	_	_	
12-17	1767-1775	recently	_	_	
12-18	1776-1782	proven	_	_	
12-19	1783-1786	its	_	_	
12-20	1787-1795	clinical	_	_	
12-21	1796-1806	usefulness	_	_	
12-22	1806-1807	.	_	_	

#Text=The photoacoustic spectroscopy utilizes a suitable substance selected from these substances and light having a wavelength at the substance selected exhibits highest absorption.
13-1	1808-1811	The	_	_	
13-2	1812-1825	photoacoustic	_	_	
13-3	1826-1838	spectroscopy	_	_	
13-4	1839-1847	utilizes	_	_	
13-5	1848-1849	a	_	_	
13-6	1850-1858	suitable	_	_	
13-7	1859-1868	substance	_	_	
13-8	1869-1877	selected	_	_	
13-9	1878-1882	from	_	_	
13-10	1883-1888	these	_	_	
13-11	1889-1899	substances	_	_	
13-12	1900-1903	and	_	_	
13-13	1904-1909	light	_	_	
13-14	1910-1916	having	_	_	
13-15	1917-1918	a	_	_	
13-16	1919-1929	wavelength	_	_	
13-17	1930-1932	at	_	_	
13-18	1933-1936	the	_	_	
13-19	1937-1946	substance	_	_	
13-20	1947-1955	selected	_	_	
13-21	1956-1964	exhibits	_	_	
13-22	1965-1972	highest	_	_	
13-23	1973-1983	absorption	_	_	
13-24	1983-1984	.	_	_	

#Text=Further it is increasingly expected that a diagnosis method be invented, which provides a two-dimensional image representing the concentration distribution of these substance.
#Text=[0008] While photoacoustic spectroscopy is used to measure substance concentration in tissue, ultrasound imaging has been extensively used for determination of the presence of morphological features, such as cysts and lumps, in human organs.
14-1	1985-1992	Further	_	_	
14-2	1993-1995	it	_	_	
14-3	1996-1998	is	_	_	
14-4	1999-2011	increasingly	_	_	
14-5	2012-2020	expected	_	_	
14-6	2021-2025	that	_	_	
14-7	2026-2027	a	_	_	
14-8	2028-2037	diagnosis	_	_	
14-9	2038-2044	method	_	_	
14-10	2045-2047	be	_	_	
14-11	2048-2056	invented	_	_	
14-12	2056-2057	,	_	_	
14-13	2058-2063	which	_	_	
14-14	2064-2072	provides	_	_	
14-15	2073-2074	a	_	_	
14-16	2075-2090	two-dimensional	_	_	
14-17	2091-2096	image	_	_	
14-18	2097-2109	representing	_	_	
14-19	2110-2113	the	_	_	
14-20	2114-2127	concentration	_	_	
14-21	2128-2140	distribution	_	_	
14-22	2141-2143	of	_	_	
14-23	2144-2149	these	_	_	
14-24	2150-2159	substance	_	_	
14-25	2159-2160	.	_	_	
14-26	2161-2162	[	_	_	
14-27	2162-2166	0008	_	_	
14-28	2166-2167	]	_	_	
14-29	2168-2173	While	_	_	
14-30	2174-2187	photoacoustic	_	_	
14-31	2188-2200	spectroscopy	_	_	
14-32	2201-2203	is	_	_	
14-33	2204-2208	used	_	_	
14-34	2209-2211	to	_	_	
14-35	2212-2219	measure	_	_	
14-36	2220-2229	substance	_	_	
14-37	2230-2243	concentration	_	_	
14-38	2244-2246	in	_	_	
14-39	2247-2253	tissue	_	_	
14-40	2253-2254	,	_	_	
14-41	2255-2265	ultrasound	_	_	
14-42	2266-2273	imaging	_	_	
14-43	2274-2277	has	_	_	
14-44	2278-2282	been	_	_	
14-45	2283-2294	extensively	_	_	
14-46	2295-2299	used	_	_	
14-47	2300-2303	for	_	_	
14-48	2304-2317	determination	_	_	
14-49	2318-2320	of	_	_	
14-50	2321-2324	the	_	_	
14-51	2325-2333	presence	_	_	
14-52	2334-2336	of	_	_	
14-53	2337-2350	morphological	_	_	
14-54	2351-2359	features	_	_	
14-55	2359-2360	,	_	_	
14-56	2361-2365	such	_	_	
14-57	2366-2368	as	_	_	
14-58	2369-2374	cysts	_	_	
14-59	2375-2378	and	_	_	
14-60	2379-2384	lumps	_	_	
14-61	2384-2385	,	_	_	
14-62	2386-2388	in	_	_	
14-63	2389-2394	human	_	_	
14-64	2395-2401	organs	_	_	
14-65	2401-2402	.	_	_	

#Text=Combining the distribution of substances and the morphological features in human tissue leads to better diagnosis and improved healthcare as it provides better characterization of the tissue, more accurate diagnosis for malignancies, and better definition of regions of abnormal pathology to guide in surgical removal of these regions.
15-1	2403-2412	Combining	_	_	
15-2	2413-2416	the	_	_	
15-3	2417-2429	distribution	_	_	
15-4	2430-2432	of	_	_	
15-5	2433-2443	substances	_	_	
15-6	2444-2447	and	_	_	
15-7	2448-2451	the	_	_	
15-8	2452-2465	morphological	_	_	
15-9	2466-2474	features	_	_	
15-10	2475-2477	in	_	_	
15-11	2478-2483	human	_	_	
15-12	2484-2490	tissue	_	_	
15-13	2491-2496	leads	_	_	
15-14	2497-2499	to	_	_	
15-15	2500-2506	better	_	_	
15-16	2507-2516	diagnosis	_	_	
15-17	2517-2520	and	_	_	
15-18	2521-2529	improved	_	_	
15-19	2530-2540	healthcare	_	_	
15-20	2541-2543	as	_	_	
15-21	2544-2546	it	_	_	
15-22	2547-2555	provides	_	_	
15-23	2556-2562	better	_	_	
15-24	2563-2579	characterization	_	_	
15-25	2580-2582	of	_	_	
15-26	2583-2586	the	_	_	
15-27	2587-2593	tissue	_	_	
15-28	2593-2594	,	_	_	
15-29	2595-2599	more	_	_	
15-30	2600-2608	accurate	_	_	
15-31	2609-2618	diagnosis	_	_	
15-32	2619-2622	for	_	_	
15-33	2623-2635	malignancies	_	_	
15-34	2635-2636	,	_	_	
15-35	2637-2640	and	_	_	
15-36	2641-2647	better	_	_	
15-37	2648-2658	definition	_	_	
15-38	2659-2661	of	_	_	
15-39	2662-2669	regions	_	_	
15-40	2670-2672	of	_	_	
15-41	2673-2681	abnormal	_	_	
15-42	2682-2691	pathology	_	_	
15-43	2692-2694	to	_	_	
15-44	2695-2700	guide	_	_	
15-45	2701-2703	in	_	_	
15-46	2704-2712	surgical	_	_	
15-47	2713-2720	removal	_	_	
15-48	2721-2723	of	_	_	
15-49	2724-2729	these	_	_	
15-50	2730-2737	regions	_	_	
15-51	2737-2738	.	_	_	
